Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601913 · ClinicalTrials.gov registry record · Early Phase 1
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT00601913 is a Early Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 24 participants.
The verdict
NCT00601913, a Early Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment with erlotinib. PURPOSE: This clinical trial is studying how well erlotinib works when given before surgery in treating patients with head and neck cancer that can be removed by surgery.
Interventions
- OTHER laboratory biomarker analysis
- GENETIC protein analysis
- OTHER immunohistochemistry staining method
- GENETIC western blotting
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-03 |
| Est. Completion | 2014-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601913
The ClinicalTrials.gov registry entry for NCT00601913 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00601913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00601913 about?
NCT00601913 is a clinical study titled "Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery". RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment with erlotinib. PURPOSE: This clinic...
What is the current status of trial NCT00601913?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2008-03. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00601913?
The interventions under investigation include: laboratory biomarker analysis (OTHER), protein analysis (GENETIC), immunohistochemistry staining method (OTHER), western blotting (GENETIC), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00601913?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.